Related Experiment Video
Updated: Sep 19, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
Blinatumomab use in pediatric B-ALL: where are we now?
Anurekha G Hall1,2, Rachel E Rau1,2
1Department of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA.
Blood Advances
|June 9, 2025
Summary
Blinatumomab is a groundbreaking therapy for B-cell acute lymphoblastic leukemia (B-ALL). This bispecific T-cell engager shows efficacy in pediatric B-ALL patients, including those with relapsed or refractory disease and newly diagnosed cases.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Blinatumomab is a bispecific T-cell engager antibody targeting CD19.
- It has shown transformative effects in B-cell acute lymphoblastic leukemia (B-ALL).
Purpose of the Study:
- To review clinical trials leading to blinatumomab approvals.
- To emphasize its application in pediatric B-ALL patients.
- To examine use in special populations and future clinical considerations.
Main Methods:
- Review of clinical trial data.
- Analysis of regulatory approval pathways.
- Examination of blinatumomab's role in various pediatric B-ALL scenarios.
Main Results:
- Blinatumomab demonstrates efficacy in relapsed/refractory pediatric B-ALL.
- It is effective as frontline therapy for newly diagnosed pediatric B-ALL.
- Regulatory approvals highlight its significance.
Conclusions:
- Blinatumomab is a key therapeutic option for pediatric B-ALL.
- Further research is needed for special populations and optimal clinical use.
- Ongoing questions address its evolving role in B-ALL treatment.
